timothy sykes logo
GCTK Stock Draws Traders As Lokahi Platform And LT-100 Advance Thumbnail
G Google News

GCTK Stock Draws Traders As Lokahi Platform And LT-100 Advance

JACK KELLOGG•UPDATED SEP. 24, 2026, 7:48 AM ET
Reviewed by Ellis Hobbsand Fact-checked by Matt Monaco

GlucoTrack Inc. stocks have been trading up by 103.94 percent amid heightened optimism over its non-invasive glucose monitoring progress.

Key Takeaways

  • Post-merger, GlucoTrack is steering capital toward Lōkahi Therapeutics, LT-100 for osteoarthritis knee pain, the ai² asset platform, and its implantable continuous glucose monitor, reshaping the GCTK story around therapeutics.
  • Lōkahi has started GMP manufacturing for LT-100, aiming to supply a once-weekly, single subcutaneous injection trial later this year, a key step toward first-in-human data.
  • The ai² platform is being split into Pipeline, Talent, and Accelerator divisions after growing to 13 university ties and screening 45+ assets, targeting diversified revenue and steady deal flow.
  • GCTK raised about $11.5M via convertible notes at an initial $3.12 conversion price with $7.50 warrants, boosting cash while adding a clear dilution overhang to the tape.
  • University collaborations with Alabama and San Diego State are expanding Lōkahi’s ai² Futures Lab, feeding more overlooked drug assets into GCTK’s early-stage pipeline in a capital-efficient way.

Candlestick Chart

Live Update At 07:47:53 EDT: On Thursday, September 24, 2026 GlucoTrack Inc. stock [NASDAQ: GCTK] is trending up by 103.94%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

GCTK has been in a steady downtrend on the daily chart. From $4.25 on 2026/08/31, GlucoTrack Inc. slid to $2.03 by 2026/09/23. Each bounce has been sold, with lower highs from $4.25 to $3.68 to the recent $2.55 and $2.47 levels. That tells traders the market is still discounting risk while the new story around Lōkahi develops.

Intraday, GCTK shows the classic low-float biotech personality. On the 5‑minute chart, the stock spiked from $3.75 at 04:00 up toward the $5.05 area by 04:20 before fading back into the low $4s. Wide candles, big wicks, and sharp reversals show how fast momentum can flip for GCTK when news hits and liquidity is thin.

More Breaking News

Fundamentals back up the “early-stage, cash-burning biotech/platform” label. In Q2 2026, GlucoTrack Inc. posted a net loss of about $3.8M and negative free cash flow of roughly $3.6M. Cash ended at $1.1M against current liabilities near $3.0M, giving a weak current ratio around 0.5 before the new financing. Returns on assets and equity are deeply negative, and book value is below zero. For traders, that means heavy reliance on the capital markets and constant sensitivity to financing terms and clinical headlines.

Why Traders Are Watching GCTK Now

GCTK has quietly shifted from a niche diabetes-device play into a broader therapeutics and platform story. After the July 14 business combination, Lōkahi Therapeutics is now the core driver inside GlucoTrack Inc., and the latest corporate update made that crystal clear. LT-100, a purified honeybee venom biologic for osteoarthritis knee pain, is the near-term flagship. The company has begun its first GMP manufacturing campaign, lining up material for a once‑weekly, single subcutaneous injection trial expected to start later this year.

For traders, that matters. Early-stage biotechs often trade on binary catalysts, and “first human dosing” is one of the big ones. GCTK’s pivot means a lot of future tape action will likely orbit around LT-100 protocol approvals, trial starts, and any safety or efficacy readouts.

But GCTK is not a one‑asset bet. Lōkahi’s ai² “actual intelligence” platform is being carved into three revenue‑oriented divisions: ai² Pipeline, ai² Talent, and ai² Accelerator. The group has grown from one to 13 university partnerships and has already screened more than 45 therapeutic assets, with several in active diligence. That’s the pipeline engine the market usually pays up for if it starts producing real deals or fee income.

On top of that, GCTK is extending programs at The University of Alabama’s Culverhouse College of Business and adding San Diego State University’s Fowler College of Business to its ai² Futures Lab. Student teams have already surfaced 45+ potential biopharma assets, some moving into pipeline talks. This is a capital‑efficient way to widen GCTK’s funnel of overlooked drugs without building a big in‑house scouting army.

The first external client for ai² PIPELINE, Innovate GBM, is another telling data point. That turns an internal tool into a fee‑for‑service business line and validates the platform concept for GCTK in the eyes of other biotech sponsors.

Conclusion

For active traders, GCTK now sits at the crossroads of three powerful forces: a new lead drug program marching toward the clinic, a scalable ai² sourcing and services platform, and a legacy glucose‑monitoring device business still alive in the background. The stock has been hit hard on the chart, but that reset also lowers the bar if any of these growth drivers show traction.

The recent $11.5M in convertible note financing gives GlucoTrack Inc. more breathing room to push LT-100 into clinical trials and keep expanding ai². The flip side is textbook small‑cap biotech: dilution risk, complex capital structure, and a balance sheet still under pressure. GCTK’s weak current ratio and negative equity underline why the company had to tap converts at a discount with $7.50 warrants attached.

This setup rewards disciplined trading. GCTK can move fast on headlines, both up and down, and the first LT-100 trial news or new ai² deals may become key catalysts. As Tim Sykes likes to say, “The market doesn’t care about your opinion, only your preparation and your plan.” As millionaire penny stock trader and teacher Tim Sykes says, “Small gains add up over time; focus on building wealth gradually, not chasing jackpots.”. For GCTK, that means knowing the levels, understanding the story around Lōkahi and ai², and being ready to cut losses quickly if the trade turns against you. This article is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”